"rationale","instanceType","uuid:ID","versionIdentifier","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","99bdfce4-e570-4851-8484-65af8a5bbed2","2","StudyVersion_1"
